April 8 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:
VANDA PHARMACEUTICALS ANNOUNCES INITIATION OF THE THETIS STUDY, A CLINICAL TRIAL OF NEREUS™ FOR THE PREVENTION OF VOMITING INDUCED BY GLP-1 RECEPTOR AGONISTS
VANDA PHARMACEUTICALS INC - TOPLINE RESULTS FROM THETIS STUDY EXPECTED BY Q4 2026
VANDA PHARMACEUTICALS INC: PHASE 2 STUDY SUCCEEDED AND MET ITS PRIMARY ENDPOINT